DIALYZABLE FACTOR BEING RESPONSIBLE FOR THE GROWTH-HORMONE HYPER-SECRETION IN DIABETIC AND NON-DIABETIC UREMIC PATIENTS - STUDIES WITH ARTIFICIAL-KIDNEY AND ARTIFICIAL PANCREAS

被引：0
|
作者：
HANSEN, AP
HANSEN, HE
ORSKOV, H
NOSADINI, R
NOY, G
ALBERTI, KGMM
机构：
[1] AARHUS UNIV,INTERNAL MED 2 CLIN,DK-8000 AARHUS C,DENMARK
[2] AARHUS UNIV,INTERNAL MED 1 CLIN,DK-8000 AARHUS C,DENMARK
[3] UNIV NEWCASTLE UPON TYNE,DEPT CLIN BIOCHEM,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND
来源：
ACTA ENDOCRINOLOGICA | 1979年 / 91卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：33 / 33
页数：1
相关论文
共 8 条
  • [1] ACETATE - INHIBITOR OF GROWTH-HORMONE HYPER-SECRETION IN DIABETIC AND NON-DIABETIC UREMIC SUBJECTS
    ORSKOV, H
    HANSEN, AP
    HANSEN, HE
    ALBERTI, KGMM
    NOY, GA
    NOSADINI, R
    ACTA ENDOCRINOLOGICA, 1982, 99 (04): : 551 - 558
  • [2] NORMALIZATION OF GLYCEMIA, GROWTH-HORMONE HYPER-SECRETION AND HYPERGLUCAGONEMIA IN UREMIC LONG-TERM DIABETICS - STUDIES WITH ARTIFICIAL-KIDNEY AND ARTIFICIAL PANCREAS
    HANSEN, AP
    HANSEN, HE
    ORSKOV, H
    NOSADRINI, R
    NOY, G
    KIDNEY INTERNATIONAL, 1979, 16 (02) : 224 - 224
  • [3] ACETATE RELEASES SOMATOSTATIN AND INHIBITS GROWTH-HORMONE HYPERPRODUCTION IN DIABETIC AND NON-DIABETIC UREMIC SUBJECTS
    ORSKOV, H
    HANSEN, AP
    HANSEN, HE
    SCHMITZ, O
    CHRISTENSEN, SE
    CORNELL, A
    DIABETOLOGIA, 1980, 19 (03) : 303 - 303
  • [4] Aliskiren and Perindopril Reduce the Levels of Transforming Growth Factor-β in Patients With Non-Diabetic Kidney Disease
    Lizakowski, Slawomir
    Tylicki, Leszek
    Renke, Marcin
    Rutkowski, Przemyslaw
    Heleniak, Zbigniew
    Slawinska-Morawska, Maja
    Aleksandrowicz-Wrona, Ewa
    Malgorzewicz, Sylwia
    Rutkowski, Boleslaw
    AMERICAN JOURNAL OF HYPERTENSION, 2012, 25 (06) : 636 - 639
  • [5] Persistence of anomalies in the growth hormone-releasing hormone-stimulated growth hormone response in diabetic-uremic patients after combined kidney-pancreas transplantation
    Malighetti, ME
    Berra, C
    Secchi, A
    Pozza, G
    Di Carlo, V
    Luzi, L
    TRANSPLANTATION, 2000, 69 (09) : 1965 - 1968
  • [6] What is the optimal range of glycemic control for non-diabetic patients undergoing gastroenterological surgery? A single-center randomized controlled trial using an artificial pancreas
    Tanioka, Nobuhisa
    Maeda, Hiromichi
    Uemura, Sunao
    Munekage, Masaya
    Kitagawa, Hiroyuki
    Namikawa, Tsutomu
    Kuroiwa, Hajime
    Fujimoto, Shimpei
    Seo, Satoru
    Hanazaki, Kazuhiro
    ARTIFICIAL ORGANS, 2023, 47 (06) : 943 - 950
  • [7] Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease
    Raji, Yemi R.
    Ajayi, Samuel
    Adeoye, Abiodun M.
    Amodu, Olukemi
    Tayo, Bamidele
    Salako, Babatunde L.
    AFRICAN HEALTH SCIENCES, 2022, 22 (01) : 344 - 351
  • [8] The relationship between insulin resistance and fibroblast growth factor 23 in patients with non-diabetic pre-dialysis chronic kidney disease: a cross-sectional study
    Durak, Beyza Algul
    Coban, Melahat
    SAO PAULO MEDICAL JOURNAL, 2025, 143 (01):
1